IgA nephropathy IgA nephropathy
Conditions
Interventions
Gargling 10 ml of DECADRON elixir 0.01% undiluted solution for 1 minute 4 times a day after every meal and before bedtime for 4 weeks.
Steroid, Gargling
Sponsors
Suzuki Yusuke
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who received renal biopsy and diagnosed as IgA nephropathy in our hospital 2) Patients who are scheduled to arrange tonsillectomy first 3) Outpatients only. 4) Patients who are older than 20 years old at the time of informed consent
Exclusion criteria
Exclusion criteria: 1) Patients who cannot provide written informed consent 2) Patients who are scheduled to arrange steroid pulse therapy first 3) Patients who are scheduled to follow up without treatemnt. 4) Patients with steroids or immunosuppressant usage prior to study entry 5) Pregnant women or lactating women 6) Patients with active intra-oral infection on examination 7) Patients who have episodes of oral candida or esophageal candida 8) Patients with rapid worsening of renal function 9) Patients with any active infection at study entry 10) Patients with malignancy at study entry 11) Patients with hepatitis C and other liver diseases 12) Any other patients that the researcher considers inappropriate for participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety of steroid gargling (Adverse effects, Clinical data, Clinical findings, degree of inflammation, glucose intolerance) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Clinical biomarkers of IgA nephropathy (serum IgA, serum Gd-IgA1, Creatinine, eGFR, urine protein/creatinine ratio, urine red blood cell count) 2) Adherence to steroid gargling therapy (treatment compliance, frequency of accidental ingestion) | — |
Contacts
Public ContactMingfeng Lee
Juntendo University Hospital
Outcome results
None listed